Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: Efficacy and toxicity

Clinical Neurology and Neurosurgery

Volumn 114, Issue 9, 2012, Pages 1222-1225

  Miglierini, Petra ^a   Bouchekoua, Mohamed ^a   Rousseau, Benoit ^b   Dam Hieu, Phong ^b,c   Malhaire, Jean Pierre ^a   Pradier, Olivier ^a  

^a CHU MORVAN   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c Research Group EA 4586 LNB   (France)

Author keywords

Gliadel wafers; Glioblastoma multiforme; Radiotherapy; Survival; Temozolomide; Toxicity

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHEMORADIOTHERAPY; DACARBAZINE; DECANOIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; POLYESTERS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866895986     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2012.02.056     Document Type: Article

References (20)

1. T.S. Surawicz, B.J. McCarthy, V. Kupelian, P.J. Jukich, J.M. Bruner, and F.G. Davis Descriptive epidemiology of primary brain and CNS tumours: results from the Central Brain Tumour Registry of the United States, 1990-1994 Neuro-oncol 1 1999 14 25
2. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. H. Brem, S. Piantadosi, P.C. Burger, M. Walker, R. Selker, and N.A. Vick Placebo-controlled trail of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas Lancet 345 8956 1995 1008 1012
4. M. Westphal, D.C. Hilt, E. Bortey, P. Delavault, R. Olivares, and P.C. Warnke A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU wafers) in patients with primary malignant glioma Neuro Oncol 5 2 2003 79 88
5. ® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir (Wien) 148 2006 269 275
6. J.N. Sarkaria, G.J. Kitange, C.D. James, R. Plummer, H. Calvert, and M. Weller Mechanisms of chemo resistance to alkylating agents in malignant glioma Clinic Cancer Res 14 10 2008 2900 2908
7. National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, published May 28, 2009 (v4.03: June 14, 2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf.
8. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Statt Assn 53 1958 457 481
9. P. Menei, P. Metellus, E. Parot-Schinke, H. Loiseau, L. Capelle, and G. Jacquet Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience Ann Surg Oncol 17 7 2010 1740 1746
10. A.M. Stark, H.H. Hugo, H.M. Mehdorn, and F. Knerlich - Lukoschus Acute hydrocephalus due to secondary leptomeningeal dissemination of an anaplastic oligodendroglioma Case Rep Med 2009 2009 370901 Epub 2009 December 20
11. S. Oshiro, F. Komatsu, H. Tsugu, K. Nabeshima, H. Abe, and M. Ohkawa A case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without typical MR appearance for CSF dissemination No Shinkei Geka 38 3 2010 279 285
12. R.V. LaRocca, J. Hodes, W.G. Villanueva, T.W. Vitaz, D.J. Morassutti, and M.J. Doyle A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion [Abstract] Neuro Oncol 8 4 2006 445
13. J.N. Rich Overall survival of primary glioblastoma (GBM) patients receiving carmustine (BCNU) wafer followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy [Abstract] J Clin Oncol 25 2007 2070
14. A. Asher Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma [Abstract] The Annual Meeting of the American Association of Neurological Surgeons Washington, DC 2007
15. S. Gururangan, I. Cokgor, J.N. Rich, S. Edwards, M.L. Affronti, and J.A. Quinn Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Neuro Oncol 3 2001 246 250
16. M. Sabel, and A. Giese Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience Curr Med Res Opin 24 11 2008 3239 3257
17. M.L. Affronti, C.R. Heery, J.E. Herndon 2nd, J.N. Rich, D.A. Reardon, and A. Desjardins Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy Cancer 115 15 2009 3501 3511
18. P.C. McGovern, E. Lautenbach, P.J. Brennan, R.A. Lustiq, and N.O. Fishman Risk factors for pastcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement Clin Infect Dis 36 6 2003 759 765
19. H.C. Bock, M.J. Puchner, F. Lohmann, M. Shütze, S. Koll, and R. Ketter First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience Neurosurg Rev 33 4 2010 441 449
20. E.L. Weber, and E.A. Goebel Cerebral oedema associated with Gliadel wafers: two case studies Neuro-oncol 7 1 2005 84 89